Financial Report: Allergan 3Q

Allergan 3Q

3Q Revenues: $1.2 billion (+6%)

3Q Loss: $668.7 million (earnings were $179.2 million in 3Q09)

YTD Revenues: $3.6 billion (+10%)

YTD Loss: $258.2 million (earnings were $401.0 million YTD09)

Comments: Total specialty pharmaceuticals sales were up 5% in the quarter and medical devices sales increased 8%. R&D expenses were $194.0 million (+10%). Results in the quarter include an aggregate charge of $369.1 million related to the impairment of Sanctura assets, as well as charges of $609.9 million for the global settlement with the DOJ related to marketing practices for certain therapeutic uses of Botox.